Imedex® is an industry leader in providing accredited, independent continuing medical education to health care professionals.

November 16, 2012

New York, New York

Optimizing Therapeutic Benefit in Advanced NSCLC: A Case-Based Discussion on the Role of Maintenance Therapy

November 16, 2012

Sheraton New York Hotel and Towers
811 7th Avenue at 52nd Street
New York, New York 10019
Tel.: +1 (212) 581-1000
Tel.: +1 (800) 325 35 35
Fax: +1 (212) 262-4410

Continuing Medical Education

Imedex®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Imedex®, LLC designates this live educational activity for a maximum 1.0 of AMA PRA Category 1 CreditTM. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Who Should Attend

This educational activity is specifically designed for medical oncologists, nurses, physician assistants, pharmacists, and other healthcare professionals involved and/or interested in the therapeutic management of patients with Thoracic Malignancies.

Objectives

After successful completion of this educational activity, participants should be able to:

  • Discuss the clinical outcomes with chemotherapeutic and targeted agents under investigation as maintenance therapy in the management of advanced NSCLC
  • Compare the benefits and risks of switch versus continuation maintenance regimens following initial therapy for advanced NSCLC
  • Determine the optimal use and patient eligibility for appropriate extended therapy following frontline treatment of advanced NSCLC
  • Prepare an evidence-based treatment plan for advanced NSCLC patients eligible for maintenance therapy with considerations of the most optimal agents, tumor biomarker profiles, and treatment-free intervals
  • Increase the frequency (compared with current) with which they plan to enroll patients in clinical trials assessing new maintenance strategies with potential to enhance outcomes in advanced NSCLC

Scientific Agenda

12:00 pm

Welcome and introduction

12:05 pm

Overview talk: Role of maintenance therapy in advanced NSCLC

  • Is maintenance therapy the standard of care in patients responding to frontline therapy?
  • Does maintenance therapy significantly prolong survival?
  • What are the drawbacks of prolonged therapy?
  • Optimal treatment-free interval
  • Selecting eligible patients for maintenance therapy

12:20 pm

Panel discussion of challenging clinical case

12:30 pm

Presentation of challenging clinical case

12:35 pm

Overview talk: Thought provoking issues in incorporating maintenance regimens

  • Switch versus continuation maintenance
  • Selection of the appropriate maintenance regimen
  • Best combination of agents
  • Can we improve on therapeutic index with biomarker profiling?

12:45 pm

Panel discussion of challenging clinical case

12:55 pm

Wrap-up: Future directions with maintenance strategies – Ongoing phase III trials

1:00 pm

Adjourn

Registration

Registration fees are complimentary for conference attendees of the 17th Annual Perspectives in Thoracic Oncology.

Support

The following company has provided an educational grant in support of this symposium:

Lilly

Organizer


11675 Rainwater Drive, Suite 600
Alpharetta, GA 30009, USA
Tel.: +1 (770) 751 7332
Fax: +1 (770) 751 7334
Email: meetings@imedex.com
Twitter: twitter.com/ImedexCME
Facebook: facebook.com/Imedex
Web: www.imedex.com

For registration inquiries:
Tel.: +1 (678) 242-0906 
Toll-free (USA only): +1 (800) 233-0957 
Fax: +1 (770) 751-7334 
Email: registration@imedex.com